Rheumatology (Oxford, England) · 2026
New phenotype and outcomes in connective tissue disease-associated pulmonary arterial hypertension: relevance of age-related comorbidities.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bravo-Marqués Rafael, Rivas-Ruiz Francisco, Tenes Andrés, Becerra-Muñoz Víctor M, Gutierrez-Ortiz Eva, de Miguel Irene Martin, Barberà Joan A, López-Meseguer Manuel, Chinchurreta Capote Pedro Antonio, Vich Isabel Blanco, Escribano-Subias Pilar, and the REHAP investigators
Аннотация
OBJECTIVES: To assess the demographic and clinical characteristics (including the burden of comorbidities) and the survival rates of patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) and to compare them with those of contemporary patients with idiopathic PAH (IPAH). We also evaluated the impact of emerging age-related comorbidities on survival.
METHODS: This was a retrospective cohort study based on data from patients included in the Spanish Registry of PAH (REHAP) during 2014-2023. Kaplan-Meier survival estimates were calculated (overall and according to ≥3 vs 1-2 or no comorbidities). Prognostic values were analysed using Cox proportional-hazards regression models.
RESULTS: A total of 340 CTD-PAH patients and 417 IPAH patients were included in the analysis (n = 757). CTD-PAH patients were older than IPAH patients [62 (14) vs 56 (17) years old] and showed lower comorbidity burden (17% vs 34% patients with ≥3 comorbidities), both P < 0.001. The 1-, 3- and 5-year survival rates were 97%, 76% and 55%, respectively, for CTD-PAH and 93%, 77% and 54%, respectively, for IPAH (P = 0.884). Of the seven comorbidities analysed, only chronic kidney disease (CKD) was associated with poor prognosis after adjustment for known PAH prognostic factors (hazard ratio 1.83; 95% CI: 1.19, 2.80), independently of aetiology. CTD-PAH received monotherapy more frequently (37% vs 52% in IPAH).
CONCLUSION: Contemporary CTD-PAH patients included in REHAP are older and have a lower comorbidity burden than IPAH patients, while exhibiting similar survival rates up to 5 years. CKD is an independent prognostic factor in both aetiologies. CTD-PAH patients tend to receive a more conservative treatment approach.
METHODS: This was a retrospective cohort study based on data from patients included in the Spanish Registry of PAH (REHAP) during 2014-2023. Kaplan-Meier survival estimates were calculated (overall and according to ≥3 vs 1-2 or no comorbidities). Prognostic values were analysed using Cox proportional-hazards regression models.
RESULTS: A total of 340 CTD-PAH patients and 417 IPAH patients were included in the analysis (n = 757). CTD-PAH patients were older than IPAH patients [62 (14) vs 56 (17) years old] and showed lower comorbidity burden (17% vs 34% patients with ≥3 comorbidities), both P < 0.001. The 1-, 3- and 5-year survival rates were 97%, 76% and 55%, respectively, for CTD-PAH and 93%, 77% and 54%, respectively, for IPAH (P = 0.884). Of the seven comorbidities analysed, only chronic kidney disease (CKD) was associated with poor prognosis after adjustment for known PAH prognostic factors (hazard ratio 1.83; 95% CI: 1.19, 2.80), independently of aetiology. CTD-PAH received monotherapy more frequently (37% vs 52% in IPAH).
CONCLUSION: Contemporary CTD-PAH patients included in REHAP are older and have a lower comorbidity burden than IPAH patients, while exhibiting similar survival rates up to 5 years. CKD is an independent prognostic factor in both aetiologies. CTD-PAH patients tend to receive a more conservative treatment approach.